CG Oncology, Inc. Common stock

, although it may do so from time to time as its management believes is appropriate or as required by applicable law. Any such updating may be made through the

Other Events. On September 5, 2025, the Company reported updated data from Cohort C of the BOND-003 Phase 3 clinical trial evaluating the efficacy and safety of

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated September 5, 2025 104 Cover Page Interactive Data File (embedd